Glycotope GmbH, a global leader in optimizing the sugar chains (glycosylation) of biopharmaceuticals, announced full details of first-in-man Phase I trial data for CetuGEXTM, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) with optimized and fully human glycosylation for a greatly enhanced anti-tumor activity and reduced side-effects. The data was presented last Monday at ASCO 2013 in the Developmental Therapeutics and Immunotherapy Session...
More...
More...